治疗对雄激素脱发的有效性

背景： 雄激素性脱发或雄性毛发损失，是由二氢睾丸激素介导的毛发障碍，是睾丸激素的有效形式。目前，米诺地尔和非那雄胺是食品和药物管理局（FDA），以及已清除FDA的Hairmax Lasercomb是FDA认可的唯一治疗方法。非外科治疗的功效与安慰剂相比，雄激素性卵猫的e源用于改善头发密度，厚度，生长（由催化剂的比例增加而定义）或患者和研究人员进行的主观全球评估。

随机审查的对照审查的指标。截至2016年12月，搜查了PubMed，Embase和Cochrane，当年没有下限。 We included only randomized controlled trials of good or fair quality based on the US Preventive Services Task Force quality assessment process.

RESULTS: A meta-analysis was conducted separately for 5 groups of studies that tested the following hair loss treatments: low-level laser light therapy in men, 5% minoxidil in men, 2%男性米诺地尔，男性1毫克的非那雄胺，女性2％的米诺地尔。在5个荟萃分析中，所有处理都优于安慰剂（p <.00001）。其他治疗方法s were not included because the appropriate data were lacking.

LIMITATIONS: High heterogeneity in most studies.

CONCLUSIONS: This meta-analysis strongly suggests that minoxidil, finasteride,低水平的激光疗法对于促进雄激素性脱发的男性的头发生长有效，而米诺地尔则对患有雄激素性脱发的女性有效。